To examine the therapeutic potential of anti-IL-17RB antibody (D9) to synergize with gemcitabine for pancreatic cancer treatment, the stemness properties of pancreatic cancer cells after anti-IL-17RB (D9) treatment were revealed. Here, IL17RB is linked to pancreatic neoplasm.